ADAR1 Capital Management LLC Acquires Shares of 3,000,000 InflaRx N.V. $IFRX

Key Points

• ADAR1 Capital Management acquired 3 million InflaRx shares in the second quarter, worth approximately $6.72 million and representing a 2.04% stake. Institutional investors collectively own 42.39% of the company.
• InflaRx shares rose 20% to $2.46, with the stock trading between $0.80 and $2.95 over the past year. The company reported a quarterly loss of $0.11 per share, missing analyst expectations of a $0.07 loss.
• Analyst sentiment is generally positive, with a consensus rating of “Moderate Buy” and an average price target of $7.33, despite one sell rating and the company’s ongoing clinical-stage losses.

ADAR1 Capital Management LLC acquired a new stake in InflaRx N.V. (NASDAQ:IFRX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 3,000,000 shares of the company's stock, valued at approximately $6,720,000. ADAR1 Capital Management LLC owned 2.04% of InflaRx as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. Cubist Systematic Strategies LLC boosted its position in InflaRx by 33.9% in the 1st quarter. Cubist Systematic Strategies LLC now owns 30,053 shares of the company's stock worth $31,000 after purchasing an additional 7,616 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in shares of InflaRx during the 2nd quarter worth approximately $25,000. Boothbay Fund Management LLC increased its holdings in shares of InflaRx by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 175,114 shares of the company's stock valued at $235,000 after purchasing an additional 17,056 shares in the last quarter. Concurrent Investment Advisors LLC increased its holdings in shares of InflaRx by 56.9% during the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company's stock valued at $53,000 after purchasing an additional 19,200 shares in the last quarter. Finally, Eversept Partners LP lifted its stake in shares of InflaRx by 1.5% in the 4th quarter. Eversept Partners LP now owns 1,757,312 shares of the company's stock valued at $1,775,000 after purchasing an additional 26,677 shares during the period. Hedge funds and other institutional investors own 42.39% of the company's stock.

InflaRx Stock Up 20.0%

Shares of NASDAQ IFRX opened at $2.46 on Wednesday. The company's 50-day simple moving average is $1.96 and its 200-day simple moving average is $1.63. InflaRx N.V. has a 52-week low of $0.80 and a 52-week high of $2.95. The firm has a market cap of $362.53 million, a price-to-earnings ratio of -4.24 and a beta of 2.48.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Equities research analysts anticipate that InflaRx N.V. will post -0.31 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the stock. HC Wainwright increased their price target on shares of InflaRx from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Monday, May 11th. Wall Street Zen raised shares of InflaRx from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Raymond James Financial upgraded shares of InflaRx from an "outperform" rating to a "strong-buy" rating and upped their price objective for the stock from $7.00 to $9.00 in a research report on Wednesday, May 13th. Zacks Research raised shares of InflaRx from a "hold" rating to a "strong-buy" rating in a research note on Monday, July 27th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of InflaRx in a research report on Wednesday, June 24th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $7.33.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

Want to see what other hedge funds are holding IFRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InflaRx N.V. (NASDAQ:IFRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source